Potassium and magnesium asparaginate - instructions for use, dose, side effects, contraindications

Potassium and magnesium asparaginate is a source of potassium and magnesium ions. Eliminates the deficiency of potassium and magnesium ions in the body, normalizes electrolyte balance, improves metabolic processes in the myocardium. The mechanism of action of the drug is associated with effective participation L-aspraginate in the transport of magnesium and potassium ions into the intracellular space.

Magnesium activates sodium potassium-ATPase, removing sodium ions from the cell and returning the potassium ions; reduces the concentration of sodium and prevents its exchange with calcium in smooth muscle vessels, reducing their resistance. Potassium stimulates the synthesis of ATP, glycogen, proteins, acetylcholine. Both ions support the polarization of cell membranes.

The drug regulates the conduct of impulses along nerve fibers, synaptic transmission, muscle contraction, the work of the heart muscle. Due to magnesium ions, it participates in the processes of energy input and consumption, normalizes membrane permeability, neuromuscular conductivity, DNA synthesis, RNA, cell growth, cell division, oxygen uptake, and phosphate synthesis.

Pharmacokinetics:The ions of potassium and magnesium are rapidly absorbed and distributed throughout the tissues of the body. About 30% of magnesium in the plasma forms complex compounds with proteins. Isolation of potassium and magnesium occurs mainly with urine, in small amounts - with feces, sweat, tears, etc. In renal failure, excretion of potassium and magnesium ions can slow down.

Indications:

Replenishing potassium and magnesium deficiency as an aid in the complex therapy for various forms of coronary heart disease (including acute myocardial infarction); chronic heart failure; cardiac arrhythmias (including on the background of an overdose of cardiac glycosides).

Contraindications:

Increased sensitivity to the drug, severe renal dysfunction, hyperkalemia, gipermagniemiya, oliguria, anuria, hemolysis, hypotension, insufficiency of adrenocortical function, Addison's disease, myasthenia gravis, dehydration, shock, acute metabolic acidosis, atrioventricular block II and III degree, hereditary fructose intolerance (preparation comprises sorbitol), Pregnancy and breast-feeding, age and 18 years of age (efficacy and safety in children below 18 years have not been established).

Carefully:

Serious liver function, metabolic acidosis, the risk of edema, decrease in renal function when it is impossible regular monitoring of serum magnesium concentration (risk of accumulation and increasing the concentration of magnesium totoxic level), hypophosphatemia, urolithic diathesis, atrioventricular blockade of the I degree.

Pregnancy and lactation:

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Dosing and Administration:

For intravenous administration. The dose of the drug is determined individually, depending on the indications for use. Before use, the contents of 1-2 ampoules of 10 ml or 2-4 ampoules of 5 ml are diluted in 100-200 ml of a 5% solution of dextrose (glucose) or 0.9% sodium chloride solution. Enter at a speed of 20-25 drops in 1 minute.

Treatment with the drug can be continued for several days before the disappearance or reduction of pathological symptoms.

Side effects:

When the recommended rate of administration is observed, adverse reactions are rarely observed.

With rapid intravenous administration, symptoms of hyperkalemia and hypermagnesemia may arise: nausea, vomiting, muscle weakness.

From the side of the central nervous system: paresthesia, paresis, hyporeflexia, coma, areflexia, respiratory depression, convulsions.

From the cardiovascular system: bradycardia, arrhythmia, a marked decrease in blood pressure, a paradoxical increase in the number of extrasystoles, atrioventricular blockade, phlebitis.

Overdose:

Overdose is possible with the administration of the drug in doses much higher than recommended.

Symptoms hyperkalemia: general weakness, paresthesia of the lower extremities, impaired sensitivity, confusion, bradycardia, arrhythmias, marked decrease in arterial pressure, vascular collapse, ventricular fibrillation, cardiac arrest during diastole.

Symptoms of hypermagnesemia: nausea, vomiting, lethargy, atony of the bladder, constipation; deterioration of atrioventricular conduction and propagation of excitation in the ventricles; the extinction of deep tendon reflexes, excessive decrease in arterial pressure, and respiratory depression.

Treatment: immediate withdrawal of the drug and the introduction of 20 % solution of sodium chloride or 10% calcium gluconate solution. Symptomatic therapy is indicated for correction of cardiovascular disorders. If necessary, hemodialysis or peritoneal dialysis is performed.

Interaction:

Simultaneous use with potassium-sparing diuretics (including triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin converting enzyme inhibitors,non-steroidal anti-inflammatory drugs may lead to the development of hyperkalemia or hypermagnesia.

An increase in the extracellular concentration of potassium ions leads to a decrease in the effectiveness of cardiac glycosides, and its reduction increases the arrhythmogenic effect of cardiac glycosides.

The use of potassium and magnesium preparations eliminates hypokalemia and deficiency of magnesium ions caused by glucocorticosteroids.

Under the influence of potassium ions, undesirable effects of cardiac glycosides decrease.

Avoid simultaneous use with aminoglycosides (neomycin, streptomycin and others), polymyxin B, tetracycline.

Avoid simultaneous use with anesthetics because of the risk of developing neuromuscular blockade (eg, respiratory depression).

Magnesium can enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracurium bezylate, decamethonium bromide, suxamethonium chloride (bromide, iodide)).

Calcium preparations reduce the effect of magnesium.

Means for general anesthesia increase the oppressive effect of magnesium preparations on the central nervous system.

Special instructions:

Use only clear solutions.In the event that when diluting the drug in a 5% solution of dextrose (glucose) or 0.9% solution of sodium chloride, cloudiness or opalescence appears, the prepared infusion solution can not be administered.

After opening the ampoule, the drug should be used immediately. Intravenous administration of the drug should be slow.

Effect on the ability to drive transp. cf. and fur:

Studies to evaluate the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions have not been carried out.

Form release / dosage:

Concentrate for the preparation of solution for infusion.

Packaging:

Primary packaging of medicinal product. 5 or 10 ml per ampoule polyethylene. The ampoules are labeled with a printer.

Secondary packaging of medicinal product. For 10 ampoules connected in cassettes with instructions for use are placed in a pack of cardboard for consumer containers. The packets are placed in a group package.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LP-004245

Date of registration:17.04.2017

Expiration Date:17.04.2022

The owner of the registration certificate:FARMASINTEZ, JSC (Irkutsk) FARMASINTEZ, JSC (Irkutsk) Russia

Manufacturer: & nbsp

FARMASINTEZ, JSC (Irkutsk) Russia

Information update date: & nbsp12.05.2017

Illustrated instructions

Instructions

Potassium and magnesium asparaginate (Potassium-magnesium asparaginate)